Dr. Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc., which uses artificial intelligence on live cancer cell analytics to predict how a patient will respond to cancer therapy drugs. He received his PhD degree in Bioengineering from Stanford University and a master’s degree in Translational Medicine from the UC Berkeley–UCSF Joint Bioengineering Program. Sungwon is a bioengineer and entrepreneur with 20 years experience in academia and biotech companies, with a focus on the development of novel cancer therapies. He is a strong advocate of functional precision medicine – personalizing a cancer treatment regimen based on each patient’s cancer cells’ functional responses to anti-cancer drugs, beyond cancer genetics.